Connor Clark & Lunn Investment Management Ltd. Has $3.56 Million Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Connor Clark & Lunn Investment Management Ltd. lifted its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 69.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 389,053 shares of the medical instruments supplier’s stock after purchasing an additional 158,897 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.96% of AngioDynamics worth $3,564,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ANGO. SBI Securities Co. Ltd. bought a new stake in AngioDynamics in the 4th quarter valued at $28,000. R Squared Ltd bought a new stake in AngioDynamics in the fourth quarter valued at about $49,000. US Bancorp DE raised its position in AngioDynamics by 1,938.0% in the fourth quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier’s stock worth $61,000 after purchasing an additional 6,376 shares in the last quarter. Quarry LP lifted its stake in AngioDynamics by 40.9% during the third quarter. Quarry LP now owns 8,518 shares of the medical instruments supplier’s stock worth $66,000 after purchasing an additional 2,471 shares during the period. Finally, SG Americas Securities LLC lifted its stake in AngioDynamics by 21.3% during the fourth quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier’s stock worth $147,000 after purchasing an additional 2,832 shares during the period. 89.43% of the stock is owned by institutional investors.

AngioDynamics Stock Performance

ANGO opened at $9.59 on Tuesday. The firm has a market cap of $388.07 million, a price-to-earnings ratio of -1.70 and a beta of 0.56. The firm’s 50-day simple moving average is $10.83 and its 200-day simple moving average is $8.65. AngioDynamics, Inc. has a twelve month low of $5.26 and a twelve month high of $13.50.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.07. The firm had revenue of $72.90 million for the quarter, compared to analysts’ expectations of $70.93 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The company’s quarterly revenue was down .1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.05) earnings per share. As a group, sell-side analysts anticipate that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright increased their target price on AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, January 10th.

Insiders Place Their Bets

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of AngioDynamics stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $12.31, for a total value of $49,978.60. Following the completion of the transaction, the senior vice president now directly owns 41,817 shares of the company’s stock, valued at $514,767.27. The trade was a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 5.40% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.